Evidence map›Paper›PMID 30471066›Full record

ArticleEuropean journal of drug metabolism and pharmacokinetics2019

Conversion from Twice-Daily Prograf

Wai-Ping Yau, Charlene Wei-Ting Loh, Anantharaman Vathsala

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of drug metabolism and pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Wai-Ping YauDepartment of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore. phaywp@nus.edu.sg.ORCID http://orcid.org/0000-0002-7852-9698
Charlene Wei-Ting LohDepartment of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Republic of Singapore.
Anantharaman VathsalaNational University Centre for Organ Transplantation, National University Hospital, Singapore, Republic of Singapore.
National University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesTacrolimus is the mainstay of immunosuppression in renal transplantation. Given that once-daily administration improves patient compliance, 1:1 dose conversion from twice-daily Prograf

methodsA prospective open-label pharmacokinetic study of 1:1 conversion from Prograf

resultsAfter conversion, without diltiazem, the area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUC

conclusionThe high prevalence of CYP3A5 polymorphism among Asians may lead to a significant reduction in tacrolimus exposure with 1:1 dose conversion of Prograf

Indexed as

AdultArea Under CurveAsian PeopleATP Binding Cassette Transporter, Subfamily BCytochrome P-450 CYP3ADiltiazemFemaleGenotypeHumansImmunosuppressive AgentsKidneyKidney TransplantationMaleMiddle AgedProspective StudiesTacrolimusABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BCYP3A5 protein, humanCytochrome P-450 CYP3ADiltiazemImmunosuppressive AgentsTacrolimus

Identifiers

PMID30471066
OpenAlexW2900830599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.